country,age,sex,lesiontype,arm,TPPCR,HDPCR,lesion4,rprquan0,rprquan6,reason_not_rand,hd_tp,excluded,lesion_location,overalloutcome
Ghana,8,Female,Papillomata,30mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,7,Female,Papillomata,30mg,1,0,Completely healed,128,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Papillomata,20mg,1,0,Completely healed,16,16,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Papillomata,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,30mg,0,0,Completely healed,4,2,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,13,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,7,Male,Papillomata,30mg,1,0,Partially healed,64,8,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,20mg,0,1,Completely healed,32,16,Randomised,TP- HD+,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,12,Female,Papillomata,30mg,1,0,Completely healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,0,0,Completely healed,64,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,5,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,20mg,1,0,Data at 4wks missing,16,8,Randomised,TP+ HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,30mg,1,1,Completely healed,32,,Randomised,TP+ HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Papillomata,20mg,1,0,Lost,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Papillomata,20mg,1,0,Completely healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Female,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,20mg,0,0,Completely healed,4,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,30mg,0,0,Partially healed,2,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,2,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,20mg,0,0,Completely healed,64,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Papillomata,30mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,30mg,0,0,Partially healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Papillomata,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,2,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,0,1,Completely healed,64,32,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,20mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,30mg,0,0,Partially healed,64,64,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Female,Papillomata,20mg,1,0,Completely healed,64,128,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,128,64,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,5,Male,Ulcer,20mg,0,0,Completely healed,,64,Randomised,TP- HD-,Missing Basline RPR,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Papillomata,30mg,1,0,Completely healed,,8,Randomised,TP+ HD-,Missing Basline RPR,Face/Neck,Exlcuded from Primary Analysis
Ghana,6,Female,Papillomata,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,13,Female,Ulcer,20mg,0,0,Partially healed,32,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,5,Male,Papillomata,20mg,1,0,Completely healed,,8,Randomised,TP+ HD-,Missing Basline RPR,Arm,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,2,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,1,0,Completely healed,,2,Randomised,TP+ HD-,Missing Basline RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Papillomata,20mg,0,0,Completely healed,,2,Randomised,TP- HD-,Missing Basline RPR,Face/Neck,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,30mg,0,0,Completely healed,8,1,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,128,64,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Female,Ulcer,20mg,0,0,Completely healed,,8,Randomised,TP- HD-,Missing Basline RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Papillomata,20mg,1,0,Completely healed,16,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,,128,Randomised,TP- HD-,Missing Basline RPR,Arm,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,0,0,Completely healed,32,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,14,Male,Ulcer,30mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,20mg,1,0,Completely healed,8,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,30mg,1,0,Completely healed,64,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,11,Female,Ulcer,20mg,0,0,Completely healed,16,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,30mg,1,0,No improvement,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,20mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Female,Ulcer,20mg,1,1,Completely healed,16,0,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Papillomata,30mg,1,0,Lost,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,5,Male,Ulcer,30mg,0,1,Completely healed,1,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Papillomata,30mg,0,0,Completely healed,32,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,1,0,Completely healed,,1,Randomised,TP+ HD-,Missing Basline RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,0,0,Partially healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,20mg,0,1,Completely healed,1,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,4,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Papillomata,30mg,1,0,Completely healed,64,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Papillomata,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,30mg,0,1,Completely healed,64,64,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Papillomata,20mg,1,0,Completely healed,32,2,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,6,Female,Papillomata,30mg,1,0,Completely healed,128,128,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Papillomata,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Female,Ulcer,20mg,1,1,Completely healed,32,,Randomised,TP+ HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,16,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Papillomata,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Back,Exlcuded from Primary Analysis
Ghana,14,Male,Papillomata,20mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,8,Male,Papillomata,20mg,1,0,Completely healed,32,2,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Papillomata,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,30mg,0,0,Partially healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Female,Papillomata,20mg,0,0,Completely healed,128,16,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,13,Female,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Female,,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,30mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,20mg,0,1,Completely healed,32,4,Randomised,TP- HD+,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,30mg,0,1,Completely healed,64,32,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,5,Female,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,16,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,2,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Papillomata,30mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Papillomata,30mg,1,0,Completely healed,32,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,6,Male,Ulcer,20mg,1,1,Partially healed,32,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Female,Ulcer,Not Randomised,,,,0,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,,,Completely healed,2,0,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,0,0,Partially healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,0,1,Completely healed,2,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,15,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,20mg,1,0,Completely healed,16,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Face/Neck,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,,,,,,T1 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Papillomata,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Face/Neck,Exlcuded from Primary Analysis
Ghana,15,Male,Papillomata,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Papillomata,20mg,1,0,Completely healed,128,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Papillomata,20mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,5,Male,Papillomata,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Trunk,Exlcuded from Primary Analysis
Ghana,5,Female,Ulcer,20mg,0,0,Partially healed,,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,14,Female,Ulcer,30mg,1,1,Completely healed,8,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Papillomata,20mg,1,0,Completely healed,8,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Papillomata,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,128,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,14,Male,Ulcer,20mg,0,0,Completely healed,16,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,1,Completely healed,1,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,5,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Face/Neck,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,0,0,Data at 4wks missing,2,0,Randomised,TP- HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,20mg,0,1,Partially healed,4,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,20mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,30mg,0,0,No improvement,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Failure & Non-Significant RPR Change
Ghana,11,Male,Papillomata,20mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,30mg,1,0,Completely healed,16,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Papillomata,30mg,1,1,Completely healed,64,1,Randomised,TP+ HD+,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,30mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,20mg,0,1,Completely healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Papillomata,30mg,1,0,Completely healed,0,32,Randomised,TP+ HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Papillomata,20mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,64,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Papillomata,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,0,No improvement,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Failure BUT Serological Cure
Ghana,6,Male,Papillomata,20mg,1,0,Completely healed,64,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,20mg,1,0,Partially healed,8,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Papillomata,20mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,4,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Papillomata,20mg,0,0,Data at 4wks missing,16,4,Randomised,TP- HD-,4 Week Lesion Data Mission,Arm,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,1,0,Completely healed,64,64,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Female,Ulcer,20mg,0,0,Completely healed,0,16,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,20mg,0,0,Data at 4wks missing,4,0,Randomised,TP- HD-,4 Week Lesion Data Mission,Arm,Exlcuded from Primary Analysis
Ghana,7,Female,Papillomata,20mg,1,0,Completely healed,64,32,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,30mg,1,0,Completely healed,0,4,Randomised,TP+ HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
Ghana,7,Female,Papillomata,20mg,1,0,Completely healed,128,32,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,20mg,0,1,Completely healed,1,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Papillomata,20mg,1,0,Completely healed,32,1,Randomised,TP+ HD-,Included in Primary Analysis,Trunk,Clinical Cure & Serological Cure
Ghana,10,Male,Papillomata,30mg,0,0,Completely healed,4,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure BUT Serological Failure
Ghana,12,Male,Papillomata,30mg,1,0,Data at 4wks missing,16,8,Randomised,TP+ HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,30mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,4,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Ulcer,20mg,0,0,Completely healed,128,1,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,10,Female,Ulcer,30mg,0,0,Completely healed,64,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,0,1,Completely healed,16,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Ulcer,20mg,1,1,Completely healed,128,32,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Papillomata,30mg,1,0,Completely healed,64,1,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,6,Male,Papillomata,30mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,7,Male,Papillomata,30mg,1,0,Completely healed,16,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,20mg,0,0,Data at 4wks missing,16,64,Randomised,TP- HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,0,0,Data at 4wks missing,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,20mg,1,0,Completely healed,4,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Papillomata,30mg,1,0,Completely healed,128,64,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,14,Female,Papillomata,30mg,1,0,Completely healed,128,64,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,14,Female,Ulcer,20mg,0,0,Data at 4wks missing,64,16,Randomised,TP- HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,15,Female,Ulcer,30mg,1,0,Completely healed,4,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,30mg,1,0,Completely healed,64,1,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,20mg,1,0,Partially healed,64,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Female,Ulcer,20mg,0,0,Completely healed,32,0,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,20mg,0,0,Completely healed,32,64,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,20mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Female,Ulcer,20mg,1,0,Completely healed,16,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Female,Ulcer,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,30mg,1,0,Completely healed,64,32,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Papillomata,30mg,1,0,Completely healed,4,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Papillomata,20mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Papillomata,30mg,1,0,Completely healed,32,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,12,Male,Papillomata,20mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,15,Male,Papillomata,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,1,0,Completely healed,4,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,30mg,0,0,Completely healed,4,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Papillomata,30mg,1,0,Completely healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,30mg,0,0,Completely healed,64,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,20mg,0,0,Completely healed,8,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Female,Ulcer,20mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,0,0,Partially healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,20mg,0,0,Completely healed,64,64,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Female,Papillomata,20mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,15,Male,Papillomata,30mg,1,0,Completely healed,64,2,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,12,Male,Papillomata,20mg,1,0,Completely healed,16,4,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,20mg,0,0,Partially healed,4,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,8,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Female,Ulcer,30mg,0,0,Completely healed,64,64,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Papillomata,20mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,30mg,0,1,Completely healed,8,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Female,Ulcer,20mg,0,1,Completely healed,2,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Papillomata,30mg,1,0,Completely healed,8,1,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,64,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Female,Papillomata,20mg,1,0,Completely healed,8,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Ulcer,Not Randomised,1,0,,,,T1 neg,TP+ HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,0,,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,1,,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,Not Randomised,0,1,,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,0,Completely healed,2,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,0,,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Papillomata,20mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Ulcer,30mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Female,Ulcer,30mg,0,1,Partially healed,32,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Papillomata,30mg,1,0,Completely healed,32,2,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,9,Male,Papillomata,20mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,7,Female,Ulcer,20mg,0,0,Completely healed,8,1,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,14,Male,Ulcer,30mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,20mg,0,0,Completely healed,16,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,4,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,1,0,Completely healed,16,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Papillomata,30mg,0,0,Completely healed,16,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Ulcer,30mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Female,Ulcer,20mg,0,0,Partially healed,16,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Female,Papillomata,20mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,30mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,20mg,1,0,Partially healed,128,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,0,Data at 4wks missing,8,8,Randomised,TP- HD-,4 Week Lesion Data Mission,Arm,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,30mg,0,0,Completely healed,1,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,30mg,0,0,Completely healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,1,0,Completely healed,64,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,1,0,Completely healed,128,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,20mg,0,1,Completely healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,20mg,0,1,Partially healed,16,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,8,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,15,Male,Ulcer,30mg,0,0,Completely healed,8,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,1,Completely healed,16,1,Randomised,TP- HD+,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,16,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,20mg,1,1,Completely healed,32,8,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,11,Female,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,0,Partially healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,1,0,Completely healed,4,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Papillomata,30mg,1,0,Completely healed,32,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,20mg,0,1,Completely healed,16,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Female,Ulcer,30mg,1,1,Completely healed,32,8,Randomised,TP+ HD+,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Female,Ulcer,20mg,0,0,Completely healed,64,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,1,,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,0,Partially healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,16,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,64,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,64,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Female,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,64,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Back,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Ulcer,Not Randomised,0,0,Completely healed,,,T1 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,20mg,1,0,Completely healed,64,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,30mg,1,1,Partially healed,16,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,0,0,Completely healed,4,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,8,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,30mg,0,1,Completely healed,8,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,0,1,Completely healed,32,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,1,Completely healed,8,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,Not Randomised,0,0,Completely healed,0,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,Completely healed,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Female,Ulcer,Not Randomised,0,0,Completely healed,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,0,Partially healed,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,1,Completely healed,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,20mg,0,1,Partially healed,0,4,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,Partially healed,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,12,Female,Papillomata,30mg,1,0,Completely healed,32,1,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Female,Ulcer,30mg,1,1,Completely healed,64,2,Randomised,TP+ HD+,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,0,1,Completely healed,1,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,Not Randomised,0,0,Partially healed,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,,Not Randomised,0,0,Completely healed,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,20mg,1,0,Completely healed,16,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,20mg,0,1,Completely healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Ulcer,30mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,30mg,0,0,Completely healed,8,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,64,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,20mg,1,0,Completely healed,4,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Female,Ulcer,30mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,20mg,0,0,Completely healed,4,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,20mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,20mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,Not Randomised,,,,,,Unwell at sceening,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Female,Ulcer,20mg,0,0,Partially healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,30mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,9,Female,Ulcer,20mg,0,0,Completely healed,4,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,7,Male,Ulcer,20mg,0,0,Completely healed,16,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,8,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,20mg,1,0,Completely healed,32,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Back,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,20mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Papillomata,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Papillomata,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Papillomata,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,30mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Papillomata,20mg,,,Completely healed,32,,Randomised,,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,11,Male,Papillomata,30mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Face/Neck,Exlcuded from Primary Analysis
Ghana,14,Male,,30mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Missing,Exlcuded from Primary Analysis
Ghana,7,Male,Papillomata,20mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Back,Exlcuded from Primary Analysis
Ghana,12,Male,Papillomata,30mg,1,0,Completely healed,16,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,8,Male,Papillomata,20mg,1,1,Completely healed,32,,Randomised,TP+ HD+,Missing 6 Month Follow-up RPR,Face/Neck,Exlcuded from Primary Analysis
Ghana,10,Female,Papillomata,30mg,1,0,Completely healed,128,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Papillomata,20mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Face/Neck,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,20mg,0,1,Completely healed,8,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,10,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,12,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,10,Female,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,12,Female,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,12,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,12,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,12,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,11,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,9,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,11,Male,,Not Randomised,,,,0,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,10,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,7,Female,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,6,Male,,Not Randomised,,,,0,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,7,Male,,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,7,Male,,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,13,Female,Ulcer,20mg,0,0,Partially healed,32,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,,,Completely healed,8,2,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Ulcer,20mg,1,0,Completely healed,32,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,,,Completely healed,16,2,Randomised,,Missing Baseline PCR,Back,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,20mg,,,No improvement,4,2,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,30mg,1,0,Completely healed,64,32,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Female,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,16,Male,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,,,,0,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,0,1,Partially healed,16,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,,,Completely healed,32,8,Randomised,,Missing Baseline PCR,Arm,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,30mg,0,1,Completely healed,1,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,128,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Female,Ulcer,30mg,0,1,Completely healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Female,Ulcer,20mg,0,0,Data at 4wks missing,64,4,Randomised,TP- HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,1,Partially healed,16,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,8,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,,,Completely healed,64,16,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,20mg,,,Completely healed,32,8,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Papillomata,30mg,,,Completely healed,64,32,Randomised,,Missing Baseline PCR,Face/Neck,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,20mg,0,0,Partially healed,4,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,20mg,0,1,Completely healed,8,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,64,32,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Male,,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Papillomata,30mg,1,0,Partially healed,32,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,2,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,15,Male,Ulcer,Not Randomised,0,0,,2,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,0,,1,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Papillomata,20mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Back,Clinical Cure & Serological Cure
Ghana,11,Male,Papillomata,20mg,1,0,Completely healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Ulcer,30mg,0,1,Completely healed,32,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Female,Ulcer,Not Randomised,0,1,,4,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,30mg,0,0,Completely healed,8,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Ulcer,20mg,0,1,Completely healed,128,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,30mg,0,1,Partially healed,4,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Ulcer,Not Randomised,0,0,,1,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Ulcer,20mg,0,1,Completely healed,64,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Male,Ulcer,20mg,0,1,Completely healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,20mg,,,Completely healed,32,4,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,30mg,0,1,Completely healed,64,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,30mg,0,1,Completely healed,64,64,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Ulcer,20mg,0,1,Partially healed,8,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Female,Ulcer,30mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,15,Male,Ulcer,30mg,1,0,Completely healed,64,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,,,Completely healed,64,4,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,20mg,0,0,Completely healed,16,16,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,1,Completely healed,8,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,30mg,,,Completely healed,16,1,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,20mg,0,1,Completely healed,64,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,13,Female,Ulcer,30mg,,,Completely healed,128,128,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,1,0,,0,,T1 or T2 missing,TP+ HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,2,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,2,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Male,Ulcer,30mg,0,1,Completely healed,4,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Papillomata,30mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Female,Ulcer,30mg,0,1,Completely healed,128,64,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,30mg,0,1,Completely healed,64,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,15,Male,Ulcer,20mg,0,1,Partially healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,30mg,0,0,Completely healed,4,2,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,1,Partially healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,30mg,0,1,Completely healed,32,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Female,Papillomata,30mg,1,0,Completely healed,64,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,16,Male,Ulcer,30mg,1,0,Data at 4wks missing,32,4,Randomised,TP+ HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,20mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,7,Male,Papillomata,30mg,1,0,Completely healed,2,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,13,Female,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Papillomata,20mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,30mg,1,0,Completely healed,64,0,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,20mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,7,Male,Papillomata,20mg,1,0,Completely healed,64,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Female,Ulcer,Not Randomised,0,1,,0,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,11,Male,Papillomata,Not Randomised,1,1,Completely healed,64,32,T1 or T2 missing,TP+ HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,12,Female,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Papillomata,20mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Papillomata,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Face/Neck,Exlcuded from Primary Analysis
Ghana,8,Male,Ulcer,20mg,0,1,Completely healed,32,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,13,Female,Ulcer,30mg,1,0,Completely healed,64,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Female,Ulcer,20mg,1,1,Completely healed,64,0,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,6,Male,Papillomata,20mg,1,0,Completely healed,128,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Female,Papillomata,30mg,1,0,Completely healed,64,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,1,Completely healed,32,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,20mg,1,0,Partially healed,32,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Papillomata,30mg,1,0,Completely healed,64,4,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,20mg,0,0,Completely healed,32,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,8,Male,Papillomata,30mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,10,Male,Ulcer,30mg,0,1,Completely healed,8,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,12,Male,Ulcer,20mg,0,1,Completely healed,2,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,8,Female,,20mg,0,0,Completely healed,64,64,Randomised,TP- HD-,Included in Primary Analysis,Missing,Clinical Cure & Non-Significant RPR Change
Ghana,14,Male,Ulcer,30mg,0,1,Completely healed,1,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
Ghana,14,Male,Papillomata,30mg,1,0,Completely healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Female,Ulcer,20mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Male,Papillomata,20mg,1,0,Completely healed,16,32,Randomised,TP+ HD-,Included in Primary Analysis,Arm,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Ulcer,30mg,0,0,Partially healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
Ghana,13,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,9,Male,Papillomata,30mg,1,0,Completely healed,16,32,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,0,0,Completely healed,32,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Male,Ulcer,20mg,0,0,Completely healed,32,32,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,13,Female,Ulcer,Not Randomised,0,1,,2,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,7,Female,Papillomata,30mg,1,0,Completely healed,32,1,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,11,Male,Ulcer,20mg,1,0,Completely healed,16,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Papillomata,30mg,1,0,Partially healed,32,16,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,12,Female,Ulcer,20mg,0,1,Partially healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,5,Male,Ulcer,Not Randomised,0,1,,0,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
Ghana,14,Male,Ulcer,30mg,0,1,Partially healed,8,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,Not Randomised,0,1,,2,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,10,Male,Ulcer,20mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
Ghana,9,Male,Ulcer,30mg,0,0,Completely healed,128,128,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Non-Significant RPR Change
Ghana,10,Male,Ulcer,30mg,1,0,Data at 4wks missing,64,32,Randomised,TP+ HD-,4 Week Lesion Data Mission,Leg,Exlcuded from Primary Analysis
Ghana,6,Male,Papillomata,20mg,1,0,Completely healed,32,4,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,12,Male,Ulcer,30mg,0,0,Completely healed,64,128,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,6,Male,Papillomata,20mg,1,0,Completely healed,32,8,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
Ghana,8,Male,Ulcer,20mg,0,0,Completely healed,8,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
Ghana,11,Male,Ulcer,Not Randomised,0,0,,0,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
Ghana,6,Female,Papillomata,Not Randomised,0,1,,0,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Ulcer,Not Randomised,0,1,,,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,,,Completely healed,16,8,Randomised,,Missing Baseline PCR,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,20mg,0,1,Completely healed,4,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,20mg,0,1,Completely healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,30mg,0,1,Completely healed,1,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,30mg,0,1,Completely healed,8,0,Randomised,TP- HD+,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,14,Female,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,30mg,0,1,Completely healed,8,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Papillomata,20mg,0,0,Completely healed,32,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Female,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Arm,Clinical Cure & Serological Cure
PNG,9,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,0,1,Completely healed,16,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Female,Ulcer,30mg,0,1,Completely healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Papillomata,20mg,1,0,Completely healed,32,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Female,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,30mg,0,0,Partially healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
PNG,9,Male,Papillomata,30mg,0,1,Completely healed,16,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Female,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,5,Female,Ulcer,30mg,0,0,Completely healed,4,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,5,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,Not Randomised,0,1,,,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,5,Female,Ulcer,Not Randomised,0,1,Completely healed,,,Unable to take blood,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Female,Ulcer,20mg,0,1,Completely healed,4,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Male,Ulcer,30mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Male,Ulcer,30mg,0,0,Completely healed,32,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,10,Male,Ulcer,20mg,0,0,Completely healed,16,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Male,Ulcer,30mg,0,1,Completely healed,32,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Female,Ulcer,20mg,0,1,Completely healed,1,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Male,Ulcer,20mg,1,1,Completely healed,8,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Male,Ulcer,30mg,0,1,Partially healed,16,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,14,Female,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,15,Male,Ulcer,30mg,0,1,Completely healed,4,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,6,Male,Ulcer,30mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,30mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Male,Ulcer,30mg,0,1,Completely healed,4,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Female,Ulcer,20mg,0,1,Completely healed,64,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,30mg,0,1,Completely healed,1,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,9,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,20mg,0,1,Completely healed,32,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,20mg,0,1,Completely healed,1,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Male,Ulcer,30mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Female,Ulcer,20mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Female,Ulcer,30mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Female,Ulcer,30mg,0,0,Completely healed,1,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,14,Male,Ulcer,30mg,0,1,Completely healed,4,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,30mg,0,1,Completely healed,32,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,20mg,0,1,Completely healed,16,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Ulcer,30mg,0,0,Completely healed,2,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Female,Ulcer,20mg,0,1,Completely healed,0,1,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,0,Completely healed,0,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Arm,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,20mg,1,0,Completely healed,64,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,,,,Not Randomised,,,,,,Unknown reason,,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis
PNG,14,Female,Ulcer,20mg,0,0,Completely healed,0,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,20mg,0,1,Completely healed,8,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Female,Ulcer,30mg,0,1,Completely healed,1,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,1,Partially healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,6,Female,Ulcer,20mg,0,1,Completely healed,,0,Randomised,TP- HD+,Missing Basline RPR,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,30mg,0,0,Completely healed,8,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,30mg,0,0,Partially healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,20mg,0,0,Completely healed,16,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Female,Ulcer,30mg,0,1,Completely healed,8,8,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,7,Male,Ulcer,Not Randomised,0,1,,,,T1 or T2 missing,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,20mg,0,1,Completely healed,32,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,30mg,0,1,Partially healed,64,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,9,Female,Ulcer,30mg,0,1,Completely healed,8,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Female,Ulcer,20mg,0,0,Completely healed,8,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,30mg,1,1,Partially healed,8,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Female,Ulcer,30mg,1,1,Completely healed,32,8,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,1,Completely healed,128,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,9,Female,Papillomata,30mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
PNG,8,Female,Ulcer,30mg,0,1,Completely healed,8,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,8,Male,Papillomata,20mg,1,0,Completely healed,128,8,Randomised,TP+ HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,64,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,32,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,30mg,0,1,Completely healed,16,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,1,0,Completely healed,16,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,7,Male,Ulcer,30mg,0,0,Completely healed,16,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,5,Female,Ulcer,20mg,1,1,Completely healed,16,0,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Female,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,6,Male,Ulcer,20mg,0,1,Partially healed,16,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Female,Ulcer,30mg,1,1,Completely healed,4,,Randomised,TP+ HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,11,Female,Ulcer,30mg,0,1,Completely healed,32,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Female,Ulcer,30mg,0,0,Completely healed,16,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
PNG,5,Male,Ulcer,Not Randomised,1,1,,,,Unable to take blood,TP+ HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,5,Female,Ulcer,20mg,0,1,Completely healed,16,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,30mg,0,1,Completely healed,8,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,20mg,1,1,Completely healed,32,0,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Male,Ulcer,20mg,0,1,Completely healed,8,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Male,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
PNG,6,Male,Ulcer,30mg,0,1,Completely healed,16,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,30mg,1,1,Completely healed,8,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,20mg,1,1,Completely healed,32,8,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Male,Ulcer,20mg,0,1,Completely healed,4,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,30mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Male,Ulcer,20mg,0,1,Completely healed,4,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,20mg,0,1,Completely healed,2,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,8,Male,Ulcer,20mg,0,0,Completely healed,32,0,Randomised,TP- HD-,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
PNG,6,Male,Ulcer,30mg,1,0,Completely healed,4,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,30mg,1,1,Completely healed,8,4,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,10,Male,Ulcer,30mg,0,1,Completely healed,64,16,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Female,Ulcer,20mg,0,0,Completely healed,16,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Male,Ulcer,30mg,0,1,Completely healed,1,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Female,Ulcer,20mg,0,1,Completely healed,8,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Male,Ulcer,30mg,1,1,Completely healed,16,2,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Male,Ulcer,20mg,1,1,Completely healed,8,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Male,Ulcer,20mg,1,0,Completely healed,32,,Randomised,TP+ HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,0,1,Completely healed,64,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,9,Female,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Ulcer,20mg,1,1,Completely healed,4,0,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Female,Papillomata,30mg,1,0,Completely healed,16,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,20mg,0,0,Completely healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,30mg,0,1,Completely healed,4,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Female,Ulcer,30mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Female,Ulcer,20mg,0,0,Completely healed,2,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,10,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,11,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,20mg,1,0,Completely healed,2,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,20mg,0,0,Completely healed,16,16,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,Not Randomised,,,,,,T2 neg,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,30mg,0,0,Completely healed,2,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,30mg,0,0,Completely healed,16,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,20mg,0,0,Completely healed,2,1,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,12,Male,Ulcer,20mg,0,0,Completely healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Papillomata,30mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Male,Ulcer,20mg,1,0,Completely healed,4,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Male,Ulcer,30mg,1,0,Completely healed,8,2,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,10,Male,Ulcer,20mg,1,1,Completely healed,4,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,11,Male,Papillomata,30mg,1,0,Completely healed,16,8,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Female,Ulcer,30mg,0,0,Completely healed,2,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Female,Ulcer,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Ulcer,20mg,1,0,Completely healed,16,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,6,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,30mg,0,0,Completely healed,0,,Randomised,TP- HD-,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Papillomata,Not Randomised,,,,,,T1&T2 neg,,Patient did not meet trial inclusion criteria,Face/Neck,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,20mg,0,1,Completely healed,4,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,30mg,0,1,Completely healed,2,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,12,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Arm,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,20mg,0,0,Completely healed,32,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,7,Female,Ulcer,20mg,0,0,Completely healed,16,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,6,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,6,Male,Ulcer,30mg,0,0,Completely healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,20mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,11,Male,Ulcer,20mg,0,0,Completely healed,32,8,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,30mg,1,0,Completely healed,0,0,Randomised,TP+ HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,30mg,0,1,Completely healed,1,0,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,30mg,0,0,Completely healed,0,1,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,8,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,8,Male,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,20mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,5,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Trunk,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,30mg,0,1,Completely healed,0,,Randomised,TP- HD+,Missing 6 Month Follow-up RPR,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,30mg,0,0,Completely healed,0,0,Randomised,TP- HD-,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Arm,Exlcuded from Primary Analysis
PNG,14,Male,Ulcer,30mg,1,1,Completely healed,16,2,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Female,Ulcer,20mg,0,0,Completely healed,4,4,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,15,Male,Ulcer,Not Randomised,1,0,,,,T1&T2 neg,TP+ HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,15,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,30mg,0,1,Completely healed,8,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,16,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,9,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,15,Female,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,30mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,6,Male,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,9,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Female,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,14,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,Not Randomised,1,1,,,,T2 neg,TP+ HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Papillomata,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,0,0,,,,T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Female,Ulcer,Not Randomised,1,0,,,,T1 neg,TP+ HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Papillomata,Not Randomised,1,1,,,,T1&T2 neg,TP+ HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Ulcer,Not Randomised,1,1,,,,T1&T2 neg,TP+ HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,20mg,1,0,Completely healed,16,1,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Male,Ulcer,Not Randomised,0,0,,,,T1 or T2 missing,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Male,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Female,Ulcer,20mg,0,1,Completely healed,16,1,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,15,Male,Ulcer,20mg,0,0,Completely healed,1,0,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,30mg,0,1,Completely healed,16,4,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,14,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,30mg,1,1,Completely healed,16,2,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,8,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,15,Male,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,9,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,9,Male,Papillomata,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,11,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Male,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,7,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,8,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Face/Neck,Exlcuded from Primary Analysis
PNG,11,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,10,Male,Ulcer,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Male,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Ulcer,Not Randomised,0,0,,,,T1&T2 neg,TP- HD-,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,12,Female,Ulcer,30mg,1,1,Completely healed,32,1,Randomised,TP+ HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,13,Female,Ulcer,Not Randomised,0,1,,,,T1&T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,30mg,1,0,Completely healed,8,0,Randomised,TP+ HD-,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Female,Papillomata,20mg,0,1,Completely healed,0,0,Randomised,TP- HD+,Negative RPR at baseline,Leg,Exlcuded from Primary Analysis
PNG,13,Female,Papillomata,20mg,1,1,Completely healed,16,1,Randomised,TP+ HD+,Included in Primary Analysis,Face/Neck,Clinical Cure & Serological Cure
PNG,11,Female,Ulcer,30mg,0,1,Completely healed,32,2,Randomised,TP- HD+,Included in Primary Analysis,Leg,Clinical Cure & Serological Cure
PNG,12,Female,Ulcer,30mg,0,0,Partially healed,2,2,Randomised,TP- HD-,Included in Primary Analysis,Leg,Clinical Cure & Non-Significant RPR Change
PNG,13,Male,Ulcer,Not Randomised,0,1,,,,T2 neg,TP- HD+,Patient did not meet trial inclusion criteria,Leg,Exlcuded from Primary Analysis
PNG,,,,Not Randomised,,,,,,T1 or T2 missing,,Patient did not meet trial inclusion criteria,Missing,Exlcuded from Primary Analysis